SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-T-56932
Product Name	Isoxaflutole
CAS No.	141112-29-0
Category	Pesticide Standards
Synonyms	(5-cyclopropylisoxazol-4-yl)(2-(methylsulfonyl)-4-(trifluoromethyl)phenyl)methanone
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email **sales@clearsynth.com** for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

2.2 Label Elements

Signal Word: Warning

Hazard Statement(s)

Code	Statement
H400	Not available
H410	Not available
H361	Not available

Precautionary Statement(s)

Code	Statement
P203	Not available
P273	Not available
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P318	Not available
P391	Not available
P405	Store locked up.
P501	Dispose of contents/container in accordance with local/regional/national/international regulatio

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Isoxaflutole
CAS Number : 141112-29-0
Molecular Formula : C15H12F3NO4S
Molecular Weight : 359.32
Parent Chemical : -
Synonyms : (5-cyclopropylisoxazol-4-yl)(2-(methylsulfonyl)-4-(trifluoromethyl)phenyl)methanone
Concentration : Not available

SECTION 4: First aid measures

Not available

SECTION 5: Firefighting measures

Not available

SECTION 6: Accidental release measures

Not available

SECTION-7: Handling and storage

Not available

SECTION 8: Exposure controls / personal protection

Not available

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

Not available

SECTION 11: Toxicological information

11.1 Information on toxicological effects
- Acute toxicity: LC50 (rat) = 5,230 mg/m3/4h.
- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: Minimal eye irritation (rabbits).
- Respiratory or skin sensitization: Not a skin sensitiser.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: Cancer Classification: Likely to be Carcinogenic to Humans
- Reproductive toxicity: No data available.
- STOT-single exposure: In a 28-day preliminary dietary study in CD-1 mice (0, 175, 700, 2800 or 7000 ppm daily for 28 days), there were no treatment-related mortalities, clinical or ophthalmoscopic observations or treatment-related effects on body weight, body-weight gain or food consumption. The liver appeared to be the target organ. Treatment-related findings included increased ALAT and ASAT activity, increased liver weights, enlarged liver and white striations, and histopathological findings including centrilobular hepatocellular hypertrophy and hepatocellular necrosis. Other findings included increased extramedullary hematopoiesis in spleen and X-zone cell vacuolation in adrenal glands (females at 7000 ppm). NOAEL was 175 ppm, equal to 29 mg/kg bw/day in males and 35 mg/kg bw/day in females.
- STOT-repeated exposure: In a 90-day dietary study in CD rats (0, 1.0, 3.0, 10 or 100 mg/kg bw/day daily for 13 weeks and three days), there were no treatment-related mortalities and no treatment-related effects on body weight, body-weight gain, food consumption or food efficiency, and no significant treatment-related effects on hematological, clinical chemistry or urinalysis parameters examined. Treatment-related findings in males at 100 mg/kg bw/day included increased absolute and relative liver weights with increased incidence of periacinar hepatocytic hypertrophy (considered adaptive and not adverse). Significant treatment-related findings were observed in the eye in males at 10 mg/kg bw/day and in both sexes at 100 mg/kg bw/day, including opaque eyes and focal corneal opacity, with gross and histopathological corneal lesions (vacuolation, superficial exfoliation, epithelial thickening, necrosis and inflammation, subepithelial fibroblastic reaction, and vascularization of the stroma). There were no treatment-related effects at 1.0 or 3.0 mg/kg bw/day; NOEL was 3.0 mg/kg bw/day. In a 28-day preliminary dietary study in CD-1 mice (0, 175, 700, 2800 or 7000 ppm daily for 28 days), the liver appeared to be the target organ with treatment-related clinical chemistry, organ weight, gross pathology and histopathological findings; NOAEL was 175 ppm, equal to 29 mg/kg bw/day in males and 35 mg/kg bw/day in females.
- Aspiration hazard: No data available.

Likely routes of exposure
- LC50 Rat inhalation >5.23 mg/L 4 hr

Symptoms related to the physical, chemical and toxicological characteristics
- In a 90-day dietary study in CD rats, treatment-related clinical and ophthalmoscopic observations included increased incidences of bilateral and unilateral opaque eyes and focal corneal opacity; focal corneal opacity was first apparent during week 3 and persisted throughout the study. Histopathological findings included vacuolation and superficial exfoliation of the epithelial cells, epithelial thickening, necrosis and inflammation, subepithelial fibroblastic reaction, and vascularization of the stroma.

SECTION 12: Ecological information

Not available

SECTION 13: Disposal considerations

Not available

SECTION 14: Transport information

Not available

SECTION 15: Regulatory information

Not available

SECTION 16: Other information

Not available

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.